Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
CAMBRIDGE, Mass., May 01, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8, 2018 at 3:30 p.m. ET.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 60 days following the presentation.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
212-362-1200
